Vancocin Italia Drug Patent Portfolio
Vancocin Italia owns 1 orange book drug protected by 4 US patents Given below is the list of Vancocin Italia's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9427402 | Preparation for improving solubility of poorly soluble drug | 29 Sep, 2031 | Active |
US8530668 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | 21 Jan, 2030 | Active |
US8889722 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | 29 Jul, 2028 | Active |
US7601746 | Compounds exhibiting thrombopoietin receptor agonism | 05 Sep, 2024 | Expired |
Latest Legal Activities on Vancocin Italia's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Vancocin Italia.
Activity | Date | Patent Number |
---|---|---|
Withdrawal of Application for PTE
Critical
| 06 May, 2024 | US7601746 |
Patent Term Extension Certificate
Critical
| 06 May, 2024 | US8889722 |
Payment of Maintenance Fee, 8th Year, Large Entity | 14 Feb, 2024 | US9427402 |
Notice of Final Determination -Election Required | 09 Feb, 2024 | US8889722 |
Notice of Final Determination -Election Required | 09 Feb, 2024 | US7601746 |
Resp. to req. for info. sent under 37 CFR 1.750 | 02 Feb, 2024 | US8889722 |
Resp. to req. for info. sent under 37 CFR 1.750 | 02 Feb, 2024 | US7601746 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Jan, 2024 | US8889722 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Jan, 2024 | US7601746 |
Email Notification
Critical
| 25 Jan, 2024 | US9427402 |
Email Notification
Critical
| 25 Jan, 2024 | US7601746 |
Email Notification
Critical
| 25 Jan, 2024 | US8889722 |
Email Notification
Critical
| 25 Jan, 2024 | US8530668 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Jan, 2024 | US8530668 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Jan, 2024 | US9427402 |
Vancocin Italia's Family Patents
Vancocin Italia drugs have patent protection in a total of 19 countries. It's US patent count contributes only to 11.3% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Vancocin Italia Drug List
Given below is the complete list of Vancocin Italia's drugs and the patents protecting them.
1. Mulpleta
Mulpleta is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9427402 | Preparation for improving solubility of poorly soluble drug |
29 Sep, 2031
(6 years from now)
| Active |
US8530668 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
21 Jan, 2030
(5 years from now)
| Active |
US8889722 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
29 Jul, 2028
(3 years from now)
| Active |
US7601746 | Compounds exhibiting thrombopoietin receptor agonism |
05 Sep, 2024
(30 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mulpleta's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List